GrippeAllemagneV3, Main, Exploration, bibRecord, 000098

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.

Identifieur interne : 000098 ( Main/Exploration ); précédent : 000097; suivant : 000099

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.

Auteurs : Christiaan Dolk [Pays-Bas] ; Martin Eichner [Allemagne] ; Robert Welte [Allemagne] ; Anastassia Anastassopoulou [Allemagne] ; Laure-Anne Van Bellinghen [Belgique] ; Barbara Poulsen Nautrup [Allemagne] ; Ilse Van Vlaenderen [Belgique] ; Ruprecht Schmidt-Ott [Allemagne, Belgique] ; Markus Schwehm [Allemagne] ; Maarten Postma [Pays-Bas]

Source :

PharmacoEconomics [ 1179-2027 ] ; 2016.

RBID : pubmed:27647004

Descripteurs français

KwdFr :
- Allemagne, Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Facteurs de l'âge, Grippe humaine (), Grippe humaine (virologie), Grippe humaine (économie), Humains, Modèles statistiques, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (économie).
MESH :
- administration et posologie : Vaccins antigrippaux.
- virologie : Grippe humaine.
- économie : Grippe humaine, Vaccins antigrippaux.
- Allemagne, Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Facteurs de l'âge, Grippe humaine, Humains, Modèles statistiques.

English descriptors

KwdEn :
- Age Factors, Cost-Benefit Analysis, Germany, Humans, Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza, Human (economics), Influenza, Human (prevention & control), Influenza, Human (virology), Models, Statistical, Quality-Adjusted Life Years.
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , economics : Influenza Vaccines.
- economics : Influenza, Human.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Age Factors, Cost-Benefit Analysis, Germany, Humans, Models, Statistical, Quality-Adjusted Life Years.

Abstract

BACKGROUND

Seasonal influenza infection is primarily caused by circulation of two influenza A strain subtypes and strains from two B lineages that vary each year. Trivalent influenza vaccine (TIV) contains only one of the two B-lineage strains, resulting in mismatches between vaccine strains and the predominant circulating B lineage. Quadrivalent influenza vaccine (QIV) includes both B-lineage strains. The objective was to estimate the cost-utility of introducing QIV to replace TIV in Germany.

METHODS

An individual-based dynamic transmission model (4Flu) using German data was used to provide realistic estimates of the impact of TIV and QIV on age-specific influenza infections. Cases were linked to health and economic outcomes to calculate the cost-utility of QIV versus TIV, from both a societal and payer perspective. Costs and effects were discounted at 3.0 and 1.5 % respectively, with 2014 as the base year. Univariate and probabilistic sensitivity analyses were conducted.

RESULTS

Using QIV instead of TIV resulted in additional quality-adjusted life-years (QALYs) and cost savings from the societal perspective (i.e. it represents the dominant strategy) and an incremental cost-utility ratio (ICUR) of €14,461 per QALY from a healthcare payer perspective. In all univariate analyses, QIV remained cost-effective (ICUR <€50,000). In probabilistic sensitivity analyses, QIV was cost-effective in >98 and >99 % of the simulations from the societal and payer perspective, respectively.

CONCLUSION

This analysis suggests that QIV in Germany would provide additional health gains while being cost-saving to society or costing €14,461 per QALY gained from the healthcare payer perspective, compared with TIV.

DOI: 10.1007/s40273-016-0443-7
PubMed: 27647004

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000078
to stream Main, to step Curation: 000078

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.</title>
<author><name sortKey="Dolk, Christiaan" sort="Dolk, Christiaan" uniqKey="Dolk C" first="Christiaan" last="Dolk">Christiaan Dolk</name>
<affiliation wicri:level="4"><nlm:affiliation>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen, The Netherlands. christiaandolk@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
</author>
<author><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
<affiliation wicri:level="1"><nlm:affiliation>Epimos GmbH, Uhlandstrasse 3, 72144, Dusslingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Epimos GmbH, Uhlandstrasse 3, 72144, Dusslingen</wicri:regionArea>
<wicri:noRegion>72144, Dusslingen</wicri:noRegion>
<wicri:noRegion>72144, Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Epidemiology and Applied Biometry, Tübingen University, Silcherstrasse 5, 72076, Tübingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Clinical Epidemiology and Applied Biometry, Tübingen University, Silcherstrasse 5, 72076, Tübingen</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Tübingen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Welte, Robert" sort="Welte, Robert" uniqKey="Welte R" first="Robert" last="Welte">Robert Welte</name>
<affiliation wicri:level="3"><nlm:affiliation>GSK Germany, Prinzregentenplatz 9, 81675, München, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>GSK Germany, Prinzregentenplatz 9, 81675, München</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Anastassopoulou, Anastassia" sort="Anastassopoulou, Anastassia" uniqKey="Anastassopoulou A" first="Anastassia" last="Anastassopoulou">Anastassia Anastassopoulou</name>
<affiliation wicri:level="3"><nlm:affiliation>GSK Germany, Prinzregentenplatz 9, 81675, München, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>GSK Germany, Prinzregentenplatz 9, 81675, München</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Bellinghen, Laure Anne" sort="Van Bellinghen, Laure Anne" uniqKey="Van Bellinghen L" first="Laure-Anne" last="Van Bellinghen">Laure-Anne Van Bellinghen</name>
<affiliation wicri:level="1"><nlm:affiliation>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden</wicri:regionArea>
<wicri:noRegion>Bonheiden</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Poulsen Nautrup, Barbara" sort="Poulsen Nautrup, Barbara" uniqKey="Poulsen Nautrup B" first="Barbara" last="Poulsen Nautrup">Barbara Poulsen Nautrup</name>
<affiliation wicri:level="3"><nlm:affiliation>EAH-Consulting, Karlsgraben 12, 52064, Aachen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>EAH-Consulting, Karlsgraben 12, 52064, Aachen</wicri:regionArea>
<placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
<settlement type="city">Aix-la-Chapelle</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Vlaenderen, Ilse" sort="Van Vlaenderen, Ilse" uniqKey="Van Vlaenderen I" first="Ilse" last="Van Vlaenderen">Ilse Van Vlaenderen</name>
<affiliation wicri:level="1"><nlm:affiliation>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden</wicri:regionArea>
<wicri:noRegion>Bonheiden</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schmidt Ott, Ruprecht" sort="Schmidt Ott, Ruprecht" uniqKey="Schmidt Ott R" first="Ruprecht" last="Schmidt-Ott">Ruprecht Schmidt-Ott</name>
<affiliation wicri:level="3"><nlm:affiliation>GSK Germany, Prinzregentenplatz 9, 81675, München, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>GSK Germany, Prinzregentenplatz 9, 81675, München</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Avenue Fleming 20, 1300, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schwehm, Markus" sort="Schwehm, Markus" uniqKey="Schwehm M" first="Markus" last="Schwehm">Markus Schwehm</name>
<affiliation wicri:level="3"><nlm:affiliation>ExploSYS GmbH, Otto-Hahn-Weg 6, 70771, Leinfelden-Echterdingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>ExploSYS GmbH, Otto-Hahn-Weg 6, 70771, Leinfelden-Echterdingen</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Stuttgart</region>
<settlement type="city">Stuttgart</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Postma, Maarten" sort="Postma, Maarten" uniqKey="Postma M" first="Maarten" last="Postma">Maarten Postma</name>
<affiliation wicri:level="4"><nlm:affiliation>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Science in Healthy Aging and healthcaRE (SHARE), University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Institute for Science in Healthy Aging and healthcaRE (SHARE), University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ</wicri:regionArea>
<wicri:noRegion>9713 GZ</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Epidemiology, University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ</wicri:regionArea>
<wicri:noRegion>9713 GZ</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27647004</idno>
<idno type="pmid">27647004</idno>
<idno type="doi">10.1007/s40273-016-0443-7</idno>
<idno type="wicri:Area/Main/Corpus">000078</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000078</idno>
<idno type="wicri:Area/Main/Curation">000078</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000078</idno>
<idno type="wicri:Area/Main/Exploration">000078</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.</title>
<author><name sortKey="Dolk, Christiaan" sort="Dolk, Christiaan" uniqKey="Dolk C" first="Christiaan" last="Dolk">Christiaan Dolk</name>
<affiliation wicri:level="4"><nlm:affiliation>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen, The Netherlands. christiaandolk@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
</author>
<author><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
<affiliation wicri:level="1"><nlm:affiliation>Epimos GmbH, Uhlandstrasse 3, 72144, Dusslingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Epimos GmbH, Uhlandstrasse 3, 72144, Dusslingen</wicri:regionArea>
<wicri:noRegion>72144, Dusslingen</wicri:noRegion>
<wicri:noRegion>72144, Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Epidemiology and Applied Biometry, Tübingen University, Silcherstrasse 5, 72076, Tübingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Clinical Epidemiology and Applied Biometry, Tübingen University, Silcherstrasse 5, 72076, Tübingen</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Tübingen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Welte, Robert" sort="Welte, Robert" uniqKey="Welte R" first="Robert" last="Welte">Robert Welte</name>
<affiliation wicri:level="3"><nlm:affiliation>GSK Germany, Prinzregentenplatz 9, 81675, München, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>GSK Germany, Prinzregentenplatz 9, 81675, München</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Anastassopoulou, Anastassia" sort="Anastassopoulou, Anastassia" uniqKey="Anastassopoulou A" first="Anastassia" last="Anastassopoulou">Anastassia Anastassopoulou</name>
<affiliation wicri:level="3"><nlm:affiliation>GSK Germany, Prinzregentenplatz 9, 81675, München, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>GSK Germany, Prinzregentenplatz 9, 81675, München</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Bellinghen, Laure Anne" sort="Van Bellinghen, Laure Anne" uniqKey="Van Bellinghen L" first="Laure-Anne" last="Van Bellinghen">Laure-Anne Van Bellinghen</name>
<affiliation wicri:level="1"><nlm:affiliation>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden</wicri:regionArea>
<wicri:noRegion>Bonheiden</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Poulsen Nautrup, Barbara" sort="Poulsen Nautrup, Barbara" uniqKey="Poulsen Nautrup B" first="Barbara" last="Poulsen Nautrup">Barbara Poulsen Nautrup</name>
<affiliation wicri:level="3"><nlm:affiliation>EAH-Consulting, Karlsgraben 12, 52064, Aachen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>EAH-Consulting, Karlsgraben 12, 52064, Aachen</wicri:regionArea>
<placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
<settlement type="city">Aix-la-Chapelle</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Vlaenderen, Ilse" sort="Van Vlaenderen, Ilse" uniqKey="Van Vlaenderen I" first="Ilse" last="Van Vlaenderen">Ilse Van Vlaenderen</name>
<affiliation wicri:level="1"><nlm:affiliation>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden</wicri:regionArea>
<wicri:noRegion>Bonheiden</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schmidt Ott, Ruprecht" sort="Schmidt Ott, Ruprecht" uniqKey="Schmidt Ott R" first="Ruprecht" last="Schmidt-Ott">Ruprecht Schmidt-Ott</name>
<affiliation wicri:level="3"><nlm:affiliation>GSK Germany, Prinzregentenplatz 9, 81675, München, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>GSK Germany, Prinzregentenplatz 9, 81675, München</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Avenue Fleming 20, 1300, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schwehm, Markus" sort="Schwehm, Markus" uniqKey="Schwehm M" first="Markus" last="Schwehm">Markus Schwehm</name>
<affiliation wicri:level="3"><nlm:affiliation>ExploSYS GmbH, Otto-Hahn-Weg 6, 70771, Leinfelden-Echterdingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>ExploSYS GmbH, Otto-Hahn-Weg 6, 70771, Leinfelden-Echterdingen</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Stuttgart</region>
<settlement type="city">Stuttgart</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Postma, Maarten" sort="Postma, Maarten" uniqKey="Postma M" first="Maarten" last="Postma">Maarten Postma</name>
<affiliation wicri:level="4"><nlm:affiliation>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Science in Healthy Aging and healthcaRE (SHARE), University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Institute for Science in Healthy Aging and healthcaRE (SHARE), University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ</wicri:regionArea>
<wicri:noRegion>9713 GZ</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Epidemiology, University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ</wicri:regionArea>
<wicri:noRegion>9713 GZ</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">PharmacoEconomics</title>
<idno type="eISSN">1179-2027</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Cost-Benefit Analysis</term>
<term>Germany</term>
<term>Humans</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (economics)</term>
<term>Influenza, Human (economics)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Models, Statistical</term>
<term>Quality-Adjusted Life Years</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne</term>
<term>Analyse coût-bénéfice</term>
<term>Années de vie ajustées sur la qualité</term>
<term>Facteurs de l'âge</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (économie)</term>
<term>Humains</term>
<term>Modèles statistiques</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (économie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Cost-Benefit Analysis</term>
<term>Germany</term>
<term>Humans</term>
<term>Models, Statistical</term>
<term>Quality-Adjusted Life Years</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Allemagne</term>
<term>Analyse coût-bénéfice</term>
<term>Années de vie ajustées sur la qualité</term>
<term>Facteurs de l'âge</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Modèles statistiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Seasonal influenza infection is primarily caused by circulation of two influenza A strain subtypes and strains from two B lineages that vary each year. Trivalent influenza vaccine (TIV) contains only one of the two B-lineage strains, resulting in mismatches between vaccine strains and the predominant circulating B lineage. Quadrivalent influenza vaccine (QIV) includes both B-lineage strains. The objective was to estimate the cost-utility of introducing QIV to replace TIV in Germany.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>An individual-based dynamic transmission model (4Flu) using German data was used to provide realistic estimates of the impact of TIV and QIV on age-specific influenza infections. Cases were linked to health and economic outcomes to calculate the cost-utility of QIV versus TIV, from both a societal and payer perspective. Costs and effects were discounted at 3.0 and 1.5 % respectively, with 2014 as the base year. Univariate and probabilistic sensitivity analyses were conducted.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Using QIV instead of TIV resulted in additional quality-adjusted life-years (QALYs) and cost savings from the societal perspective (i.e. it represents the dominant strategy) and an incremental cost-utility ratio (ICUR) of €14,461 per QALY from a healthcare payer perspective. In all univariate analyses, QIV remained cost-effective (ICUR <€50,000). In probabilistic sensitivity analyses, QIV was cost-effective in >98 and >99 % of the simulations from the societal and payer perspective, respectively.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>This analysis suggests that QIV in Germany would provide additional health gains while being cost-saving to society or costing €14,461 per QALY gained from the healthcare payer perspective, compared with TIV.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27647004</PMID>
<DateCompleted><Year>2017</Year>
<Month>10</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-2027</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>34</Volume>
<Issue>12</Issue>
<PubDate><Year>2016</Year>
<Month>12</Month>
</PubDate>
</JournalIssue>
<Title>PharmacoEconomics</Title>
<ISOAbbreviation>Pharmacoeconomics</ISOAbbreviation>
</Journal>
<ArticleTitle>Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.</ArticleTitle>
<Pagination><MedlinePgn>1299-1308</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="BACKGROUND">Seasonal influenza infection is primarily caused by circulation of two influenza A strain subtypes and strains from two B lineages that vary each year. Trivalent influenza vaccine (TIV) contains only one of the two B-lineage strains, resulting in mismatches between vaccine strains and the predominant circulating B lineage. Quadrivalent influenza vaccine (QIV) includes both B-lineage strains. The objective was to estimate the cost-utility of introducing QIV to replace TIV in Germany.</AbstractText>
<AbstractText Label="METHODS">An individual-based dynamic transmission model (4Flu) using German data was used to provide realistic estimates of the impact of TIV and QIV on age-specific influenza infections. Cases were linked to health and economic outcomes to calculate the cost-utility of QIV versus TIV, from both a societal and payer perspective. Costs and effects were discounted at 3.0 and 1.5 % respectively, with 2014 as the base year. Univariate and probabilistic sensitivity analyses were conducted.</AbstractText>
<AbstractText Label="RESULTS">Using QIV instead of TIV resulted in additional quality-adjusted life-years (QALYs) and cost savings from the societal perspective (i.e. it represents the dominant strategy) and an incremental cost-utility ratio (ICUR) of €14,461 per QALY from a healthcare payer perspective. In all univariate analyses, QIV remained cost-effective (ICUR <€50,000). In probabilistic sensitivity analyses, QIV was cost-effective in >98 and >99 % of the simulations from the societal and payer perspective, respectively.</AbstractText>
<AbstractText Label="CONCLUSION">This analysis suggests that QIV in Germany would provide additional health gains while being cost-saving to society or costing €14,461 per QALY gained from the healthcare payer perspective, compared with TIV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dolk</LastName>
<ForeName>Christiaan</ForeName>
<Initials>C</Initials>
<Identifier Source="ORCID">0000-0001-7191-115X</Identifier>
<AffiliationInfo><Affiliation>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen, The Netherlands. christiaandolk@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eichner</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Epimos GmbH, Uhlandstrasse 3, 72144, Dusslingen, Germany.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Clinical Epidemiology and Applied Biometry, Tübingen University, Silcherstrasse 5, 72076, Tübingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Welte</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>GSK Germany, Prinzregentenplatz 9, 81675, München, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Anastassopoulou</LastName>
<ForeName>Anastassia</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>GSK Germany, Prinzregentenplatz 9, 81675, München, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Van Bellinghen</LastName>
<ForeName>Laure-Anne</ForeName>
<Initials>LA</Initials>
<AffiliationInfo><Affiliation>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Poulsen Nautrup</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>EAH-Consulting, Karlsgraben 12, 52064, Aachen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Van Vlaenderen</LastName>
<ForeName>Ilse</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>CHESS, Zwarte Leeuwstraat 69, 2820, Bonheiden, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schmidt-Ott</LastName>
<ForeName>Ruprecht</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>GSK Germany, Prinzregentenplatz 9, 81675, München, Germany.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>GSK Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schwehm</LastName>
<ForeName>Markus</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>ExploSYS GmbH, Otto-Hahn-Weg 6, 70771, Leinfelden-Echterdingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Postma</LastName>
<ForeName>Maarten</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>PharmacoEpidemiology and PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 GZ, Groningen, The Netherlands.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute for Science in Healthy Aging and healthcaRE (SHARE), University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Epidemiology, University Medical Center Groningen (UMCG), Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Pharmacoeconomics</MedlineTA>
<NlmUniqueID>9212404</NlmUniqueID>
<ISSNLinking>1170-7690</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>T</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019057" MajorTopicYN="Y">Quality-Adjusted Life Years</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Compliance with Ethical Standards Funding GlaxoSmithKline Biologicals SA funded this study (GSK Study Identifier: HO-14-14994) and was involved in all stages of the study, including analysis of the data. GlaxoSmithKline Biologicals SA also covered all costs associated with the development and publication of this manuscript. Conflict of interest AA, RSO and RW are employees of the GSK group of companies. RSO, AA and RW declare restricted shares ownership in the GSK group of companies. ME is a shareholder of Epimos GmbH, which has received funding from the GSK group of companies to complete the work disclosed here as well as consultancy fees from AstraZeneca. MS is a shareholder of ExploSYS GmbH, which has received funding from Epimos GmbH to complete the work disclosed here. BPN’s, LAVB’s and IVV’s companies received consultancy fees from the GSK group of companies to complete the work disclosed here as well as for other work outside this study. MP received grants and honoraria from various pharmaceutical companies, inclusive of those developing, manufacturing and marketing influenza vaccines. CD declares no conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>9</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>10</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>9</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27647004</ArticleId>
<ArticleId IdType="doi">10.1007/s40273-016-0443-7</ArticleId>
<ArticleId IdType="pii">10.1007/s40273-016-0443-7</ArticleId>
<ArticleId IdType="pmc">PMC5110585</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>BMC Infect Dis. 2014 Jul 03;14:365</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24993051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2005 Feb 1;191 Suppl 1:S97-106</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15627236</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Health Serv Res. 2015 Apr 03;15:141</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25884452</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2015;14(8):1055-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26098443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2012 Jan;6(1):37-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21668663</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2010 Jan 12;10:8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20067628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2014;10(5):1171-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24609063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Jun 06;9(6):e98437</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24905235</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Epidemiol. 2008 Apr 1;167(7):775-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18230677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Decis Making. 2010 Mar-Apr;30(2):194-205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20190188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Decis Making. 2003 Jan-Feb;23(1):76-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12583457</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Dec;14(12):1228-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25455990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Econ. 2015 ;18(9):746-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25903831</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Health Econ. 2012 Apr;13(2):127-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21170731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2015 Oct 27;15:465</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26503131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2008 Mar 25;5(3):e74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18366252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Thrombolysis. 2014 May;37(4):507-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24221805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2008;26(3):191-215</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18282015</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2015;11(3):564-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25714506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2016 Mar;34(3):227-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26477039</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2015 Oct;34(10):1081-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26181897</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2015 Jul 29;10(7):e0133606</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26222538</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2011 May;29(5):371-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21504239</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Belgique</li>
<li>Pays-Bas</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>Bavière</li>
<li>District de Cologne</li>
<li>District de Haute-Bavière</li>
<li>District de Stuttgart</li>
<li>District de Tübingen</li>
<li>Groningue (province)</li>
<li>Rhénanie-du-Nord-Westphalie</li>
</region>
<settlement><li>Aix-la-Chapelle</li>
<li>Groningue</li>
<li>Munich</li>
<li>Stuttgart</li>
<li>Tübingen</li>
</settlement>
<orgName><li>Université de Groningue</li>
</orgName>
</list>
<tree><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Dolk, Christiaan" sort="Dolk, Christiaan" uniqKey="Dolk C" first="Christiaan" last="Dolk">Christiaan Dolk</name>
</region>
<name sortKey="Postma, Maarten" sort="Postma, Maarten" uniqKey="Postma M" first="Maarten" last="Postma">Maarten Postma</name>
<name sortKey="Postma, Maarten" sort="Postma, Maarten" uniqKey="Postma M" first="Maarten" last="Postma">Maarten Postma</name>
<name sortKey="Postma, Maarten" sort="Postma, Maarten" uniqKey="Postma M" first="Maarten" last="Postma">Maarten Postma</name>
</country>
<country name="Allemagne"><noRegion><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
</noRegion>
<name sortKey="Anastassopoulou, Anastassia" sort="Anastassopoulou, Anastassia" uniqKey="Anastassopoulou A" first="Anastassia" last="Anastassopoulou">Anastassia Anastassopoulou</name>
<name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
<name sortKey="Poulsen Nautrup, Barbara" sort="Poulsen Nautrup, Barbara" uniqKey="Poulsen Nautrup B" first="Barbara" last="Poulsen Nautrup">Barbara Poulsen Nautrup</name>
<name sortKey="Schmidt Ott, Ruprecht" sort="Schmidt Ott, Ruprecht" uniqKey="Schmidt Ott R" first="Ruprecht" last="Schmidt-Ott">Ruprecht Schmidt-Ott</name>
<name sortKey="Schwehm, Markus" sort="Schwehm, Markus" uniqKey="Schwehm M" first="Markus" last="Schwehm">Markus Schwehm</name>
<name sortKey="Welte, Robert" sort="Welte, Robert" uniqKey="Welte R" first="Robert" last="Welte">Robert Welte</name>
</country>
<country name="Belgique"><noRegion><name sortKey="Van Bellinghen, Laure Anne" sort="Van Bellinghen, Laure Anne" uniqKey="Van Bellinghen L" first="Laure-Anne" last="Van Bellinghen">Laure-Anne Van Bellinghen</name>
</noRegion>
<name sortKey="Schmidt Ott, Ruprecht" sort="Schmidt Ott, Ruprecht" uniqKey="Schmidt Ott R" first="Ruprecht" last="Schmidt-Ott">Ruprecht Schmidt-Ott</name>
<name sortKey="Van Vlaenderen, Ilse" sort="Van Vlaenderen, Ilse" uniqKey="Van Vlaenderen I" first="Ilse" last="Van Vlaenderen">Ilse Van Vlaenderen</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000098 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000098 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeAllemagneV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27647004
   |texte=   Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27647004" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 11:47:10 2020. Site generation: Sat Sep 26 09:55:33 2020

	Corpus GrippeAllemagneV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeAllemagneV3

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki